AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03816306
Drug: LCZ 696
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 is an Angiotensin receptor neprilysin inhibitor. It's composed of Sacubitril/Valsartan. LCZ696 starting dose 50 mg P.O. BID, LCZ696 100 mg P.O. BID and up-titration to LCZ696 200 mg P.O. BID.
Trial: NCT00920608
Drug: AZD9056
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral use. 400 mg once daily for 7 days
Trial: NCT00920608
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet for oral use.7.5 to 20 mg single dose administration at visit 2 and 3.
Trial: NCT01613014
Drug: ABT-436
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target dose - 400mg BID
Trial: NCT01613014
Drug: Matched Placebo - Sugar Pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target Dose - 2 pills BID
Trial: NCT01064024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, every 8 hours for 48 hours
Trial: NCT00003662
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00711269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00537550
Drug: Vincristin, Daunorubicine, Asparaginase, Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy
Trial: NCT01822041
Drug: ARN-509
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 240 mg ARN-509
Trial: NCT01266655
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00385567
Drug: PEHRG214
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00926796
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Four 500 mg tablets will be administered orally to equal a 2 gm dose.
Trial: NCT00926796
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fixed dose of 240 mg intramuscular one time for patients \>45 kg and a 5 mg/kg dose for patients less than or equal to 45 kg based on their measured weight in clinic. Most patients will require 2 injections of gentamicin in separate large muscle groups.
Trial: NCT01720615
Drug: Propofol / Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia: Loss of consciousness and standard clinical practice
Trial: NCT01720615
Drug: Sevoflurane / Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia: Loss of consciousness and standard clinical practice
Trial: NCT02840058
Drug: Anti PD1/PDL1 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03218254
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01552928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anagrelide placebo + Moxifloxacin placebo single oral dose
Trial: NCT03105596
Drug: Chidamide plus DICE Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chidamide 20mg orally d1, 4, 8, 11, 15, 18; Dexamethasone 10mg，ivg, d1-4; ifosfamide 1g/m2, ivg, d1-4, given over 4 hours; Mesna 0.4g, 0,4,8,12 hours during Ifosfamide transfusion, ivg, d1-4; Cisplatin 25mg/m2, ivg, d1-4; Etoposide 60mg/m2, ivg. d1-4.
Trial: NCT03064295
Drug: Contrast
RxNorm normalized name: CONTRAST MEDIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intravenous gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg)
Trial: NCT03064295
Drug: Pharmacologic Stress Agent
RxNorm normalized name: COPD pharmacologic substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The stress agent administered intravenously is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
Trial: NCT04570657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive multiple doses of placebo
Trial: NCT00631657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo tablet once a day
Trial: NCT00761657
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule
Trial: NCT02307721
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone. After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4. In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.
Trial: NCT03593538
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose filler in gel capsules
Trial: NCT02998554
Drug: SHP640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instill 1 drop of SHP640 (PVP-I 0.6% and Dexamethasone 0.1%) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
Trial: NCT02998554
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
Trial: NCT01176097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension,single doses
Trial: NCT01717664
Drug: RHB-104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
Trial: NCT00859781
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)
Trial: NCT01008995
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection at Week 0 and 4
Trial: NCT01008995
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection at Week 12
Trial: NCT04584112
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 60 mg/m\^2 Q2W administered by IV infusion.
Trial: NCT01679080
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: antiresorptive and calcium and vitamin D
Trial: NCT04584112
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 600 mg/m\^2 Q2W administered by IV infusion.
Trial: NCT00251407
Drug: CPT-11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
Trial: NCT01589718
Drug: Sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subject in cohort 2 will receive one sham comparator, sham injection prior to vitreous surgery.
Trial: NCT02645903
Drug: standard general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cases to whom applied alone standard general anesthesia were determined as Group 2
Trial: NCT01883323
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: i.v., 60mg/kg per day for 2 days
Trial: NCT01208038
Drug: Intrinsa Transdermal testosterone patch
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks
Trial: NCT01966575
Drug: Progestin
RxNorm normalized name: Progestin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental group will have no progestin prior to ovulation induction with clomiphene citrate, while the comparison group will have progestin medication prior to ovulation induction with clomiphene citrate, as per usual care.
Trial: NCT03484299
Drug: FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% dose - first 3 enrolled; 50% dose - next 3 enrolled; 75% dose - remaining 4 enrolled
Trial: NCT02274506
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg by vein on Days -8 and -7.
Trial: NCT03050359
Drug: TAK-438 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-438 placebo-matching tablets.
Trial: NCT03050359
Drug: Bismuth-Containing Quadruple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g Amoxicillin, 500 mg clarithromycin and 600 mg bismuth potassium citrate/bismuth tripotassium dicitrate, twice daily (BID).
Trial: NCT00775502
Drug: BIW-8962
RxNorm normalized name: BREATHING CIRCUIT,BIWAZE COUGH,W/MOUTHPIECE,STANDARD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of liquid dosage form. Doses 0.03, 0.10, 0.30, 1.0, 3.0, and 10 mg/kg. Frequency is once every two weeks. Duration is 6 months
Trial: NCT00649376
Drug: Allegra® Tablets 180 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 180mg, single dose fasting
Trial: NCT01371487
Drug: GSK1120212
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral/once-daily single doses on Day 1 of Periods 1 and 2
Trial: NCT02753036
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard combination chemotherapy (paclitaxel +/- carboplatin) if necessary according to treatment guidelines
Trial: NCT04336722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo identical in appearance to experimental drug (odevixibat).
Trial: NCT04536636
Drug: Control-No drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received usual medical care with no DHA
Trial: NCT02304783
Drug: Piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients allocated to this arm received, as a second line treatment of renal colics, a five days treatment with 20 mg piroxicam associated with placebo per day and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
Trial: NCT02304783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to this arm received a five days treatment with Placebo and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
Trial: NCT00264550
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive methotrexate capsules weekly.
Trial: NCT00264550
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive subcutaneous (SC) injections of placebo every 4 weeks.
Trial: NCT01555112
Drug: Topical AS101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS101 15% ointment will be applied topically twice daily on external genital warts for up to 16 weeks.
Trial: NCT00264550
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo capsules weekly
Trial: NCT02227017
Drug: TPV capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02227017
Drug: TPV solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02227017
Drug: RTV capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02227017
Drug: RTV solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03274492
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT03274492
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
Trial: NCT00000542
Drug: chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000542
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01362803
Drug: AZD6244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6244 orally (at recommended Ph2 dose) every 12 hours on continuous daily schedule for cycles of 28 days until unacceptable toxicity, patient withdrawal or PD
Trial: NCT04149899
Drug: WB007 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WB007 Ophthalmic Solution 0.05%
Trial: NCT04149899
Drug: WB007 0.15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WB007 Ophthalmic Solution 0.15%
Trial: NCT04149899
Drug: WB007 0.4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WB007 Ophthalmic Solution 0.4%
Trial: NCT00882726
Drug: CNTO 3649 SC (Diabetic patients)
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetic patients will receive multiple doses of CNTO 3649 (30, 100 or 300 microgram per kilogram, subject to change) as subcutaneous injections once weekly for 4 consecutive weeks.
Trial: NCT00882726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants within each dosing group who are randomized to placebo will receive a corresponding IV infusion or SC injection of placebo.
Trial: NCT01192906
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doses, once a day for 52 weeks
Trial: NCT00976911
Drug: liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg/m2 iv every 4 weeks
Trial: NCT01757782
Drug: Placebo (distilled water)
RxNorm normalized name: petroleum distillate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distill water oral
Trial: NCT00126399
Drug: doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01580592
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, s.c., every 4 weeks
Trial: NCT00783341
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04043338
Drug: XC130-A10H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XC130-A10H supplied as a 0.2, 0.4, 0.8, 1.6 or 3.2 mg dose, administered in capsules or tablets
Trial: NCT04043338
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplied as matching capsules or tablets
Trial: NCT04392102
Drug: ZL-2306(Niraparib）
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
Trial: NCT02985268
Drug: Optimal Medical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy administered as per the Guideline Direct Medical Therapy (GDMT) as defined in the 2013 ACCF/AHA Heart Failure Guidelines with maximum tolerated doses of an ACE-inhibitor or Angiotensin Receptor Blocker (ARB) and beta-blocker
Trial: NCT04229498
Drug: Monotherapy and combination therapy (all antibiotics that are given by attending pysicians and can be active against Klebsiella pneumoniae will be evaluated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In carbapenem heteroresistant Klebsiella pneumoniae group, carbapenem monotherapy (ertapenem, imipenem, meropenem) vs other treatment groups will also be compared
Trial: NCT00610727
Drug: Inhaled placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato Placebo (0 mg)
Trial: NCT03229408
Drug: Salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lean PCOS Arms: Salsalate 1.5 gm PO bid; Obese PCOS Arm: Salsalate 2.0 gm PO bid
Trial: NCT02465060
Drug: Fexagratinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01327651
Drug: Daily dosing
RxNorm normalized name: Osmolex 322 MG Daily Dosing Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate.
Trial: NCT01327651
Drug: Time-driven dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF/FTC twice weekly with a post-exposure dose
Trial: NCT04069156
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be randomized to either Placebo or Aspirin post implant
Trial: NCT01994291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo is provided in tablet form to match the 50mg dose of PF-04634817.~Dose is 4 tablets each day for 12 weeks
Trial: NCT01994291
Drug: Masked Sham Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empty, needle-less syringe is used by the unmasked team once a month.
Trial: NCT01577589
Drug: Placebo in 50 ml infusion volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT01577589
Drug: Placebo in 250 ml infusion volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT01577589
Drug: Placebo in 100 ml infusion volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT02305160
Drug: Butantan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of Butantan surfactant 100 mg/kg, IT, maximum of 3 doses
Trial: NCT02193334
Drug: KP-100IT
RxNorm normalized name: Draxxin KP
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02193334
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01161134
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meloxicam Tablets 15 mg
Trial: NCT00026299
Drug: ZD1839
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01352416
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
Trial: NCT02052011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00658047
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10mg/week for 2 weeks escalated to 15mg/week for 2 weeks escalated to 20mg/week for 8 weeks
Trial: NCT04124042
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a sterile phosphate-buffered saline
Trial: NCT03520647
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: This research protocol is therefore designed to evaluate the safety and effectiveness of using an unmanipulated G-CSF mobilized peripheral stem cell allograft from a haploidentical donor and post-transplant cyclophosphamide for patients with SAA, or SAA evolving to MDS, or PNH that has proven to be refractory to conventional immunosuppressive therapy (IST) in patients who lack an HLA-matched donor (sibling/ or matched unrelated donor.
Trial: NCT02960490
Drug: E6011
RxNorm normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous administration
Trial: NCT02960490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous administration
Trial: NCT00549679
Drug: GSK256066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDE4 inhibitor
Trial: NCT00549679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03900754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02248883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02248883
Drug: RTV
RxNorm normalized name: Accu-Chek SmartView Test Strips
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01333397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I.M. on day 1 (single treatment cycle)
Trial: NCT00428116
Drug: HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination first line antiretrovirals as previously described.
Trial: NCT00074828
Drug: LY517717
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01349777
Drug: Pregrel®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregrel® 75mg daily for 12 months
Trial: NCT01349777
Drug: Plavix®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plavix® 75mg daily for 12 months
Trial: NCT00206323
Drug: placebo/sugar pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03477903
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride for injection
Trial: NCT00418002
Drug: AQW051
FDA approved: no
EMA approved: no
PMDA approved: no